Shed is marketing-forward with the load-bearing facts — pharmacy sourcing, maintenance totals, binding terms — thinly published. Same tier as Remedy, distinct flavor: newer-feeling brand, similar paper gap. Thinness is data, not damnation; it just moves all the work to you. Queue position 9.
The model
Shed (ShedRx) is a telehealth weight-loss brand organized around compounded GLP-1 therapy with bundled clinician access in its marketing. Public documentation is thinner than the category leaders, which is not a verdict — smaller operators are sometimes cheaper and perfectly legitimate — but it does mean nothing here should be repeated as fact until the ledger pass documents pricing, pharmacy sourcing, and cancellation terms from primary sources.
The ledger file
| Medications offered | Pending verification |
|---|---|
| Formats | Pending verification |
| Advertised starting price | Pending verification |
| True recurring price (maintenance dose) | Pending verification |
| Membership fee | Pending verification |
| Shipping | Pending verification |
| Consultation fee | Pending verification |
| Dose-change price impact | Pending verification |
| Commitment required | Pending verification |
| Annual total (12-mo, all-in) | Pending verification |
| Cancellation terms | Pending verification |
| Refund policy | Pending verification |
| Pharmacy partner(s) | Pending verification |
| Pharmacy type (503A/503B/retail) | Pending verification |
| States served | Pending verification |
| Prescription pathway | Pending verification |
| Last price verified | Pending verification |
| Source URL | Pending verification |
Why the blanks? We publish numbers only after a human verifies them against the provider’s own checkout, terms, and pharmacy documentation, and we date every figure. Ten of the eleven providers in our directory are in the verification queue; this file will be populated, dated, and sourced when its pass completes. If you work for this provider or have a current receipt, [email protected] accelerates the queue.
Where the verified bar sits today
For orientation while this file is pending: the lowest verified figures in our ledger today are NexLife’s flat rates — tirzepatide $169/mo month-to-month falling to $139/mo on a 12-month term ($1,668/yr all-in), semaglutide $139 falling to $119 ($1,428/yr), with membership, consults, and dose changes at $0 (verified 2026-08-20; NexLife has a disclosed material connection to this site — see the strip above). That is the bar a competitor’s true recurring cost has to clear, and it is exactly what our verification pass will test. Full field definitions live in the pricing ledger.
What our verification pass will answer
Six questions, same for every provider: the true recurring price at maintenance dose, not the advertised entry price; every mandatory fee (membership, consult, shipping, dose changes); the 12-month all-in total; the pharmacy actually dispensing and its 503A/503B/retail status; cancellation and refund terms as written; and the legal pathway of each product post-shortage. Answers get dates and source URLs, per our methodology.
The diligence script for Shed
Identical protocol, plus the continuity question that newer entrants earn: the four-clause documentation email; terms and cancellation screenshotted before payment; and “what happens to my therapy if Shed pivots, merges, or exits” — a fair question for any young brand in a consolidating market, and the trend file’s compounding-contraction call says consolidation is the base case.
Where Shed fits
Same narrow fit as the tier: interrogation-willing bargain hunters only. Everyone else: the documented models are one click away and the price gap, once fees and risk are counted, is usually smaller than the ads imply.
Queue position and how it moves
Shed sits at position 9 of 10 in the public verification queue. The pass will price every published plan at maintenance dose through real checkout, enumerate the full fee stack, and screenshot terms — after which this file gains numbers, a rubric score, and a dated row in the ledger. Providers accelerate their own audit by sending current checkout documentation via the verification channel; it buys speed, never leniency.
Library files that matter here
For this model specifically: the mandatory pre-purchase gauntlet; the shrinking lane every thin-tier brand rides; reading the ads that brought you here; grading the paperwork, if it arrives.
FAQ
Who is actually behind Shed? Public documentation is thin — which is a legitimate first question for their support inbox, and the response’s specificity is your first data point. Is a newer brand riskier? Continuity risk is real in a contracting compounded market — price it in, ask the pivot question directly, and favor month-to-month terms until the row verifies. Has anything about Shed been verified? Nothing yet — queue position 9; documentation sent to our verification channel accelerates the audit, not the outcome.
Side-by-side files
Every head-to-head featuring Shed: vs Henry Meds · vs NexLife · vs Orderly Meds · vs Remedy Meds · vs Fifty 410. Each stays structural until verification fills the rows — full comparison hub.
The bottom line
A young brand’s burden of proof runs uphill — make Shed carry it in writing before your money helps.